What the results of ozempic for heart patients? Recently, weight loss drugs such as semaglutide and tirzepatide have been proven to have significant cardioprotective effects. The new research suggests that the ozempic can actually benefit more patients facing the threat of heart disease and stroke.
The clinical trial data of Novo Nordisk showed that the incidence rate of heart disease in patients using Ozempic was reduced by 20%. In March of this year, the US Food and Drug Administration agreed to add cardiovascular benefit statements on the Wegovy label, making it the first weight loss drug recognized as potentially reducing the risk of heart disease, stroke, or heart related death. In addition, a study by Dandelion Health revealed that GLP-1 drugs such as semaglutide are not simply weight loss drugs.
On the contrary, these drugs actually have the potential to comprehensively improve health levels and can be seen as health promoters. This study is based on real-world data and clinical artificial intelligence of ozempic for heart patients. The results indicate that GLP-1 drugs can be used as preventive treatment options, greatly reducing the risk of mild or moderate cardiovascular disease in patients who have not experienced heart disease, providing new hope for such patients.
The research team analyzed the medical records of a group of patients who were similar to those in the Novo Nordisk clinical trial but had no history of serious cardiovascular events. By long-term tracking of medical records, particularly focusing on electrocardiogram readings or measurements of cardiac electrical activity, researchers use artificial intelligence models to predict the potential risk reduction effect of GLP-1 on heart disease or stroke, and validate it through actual events.
The research results show that GLP-1 drugs can effectively reduce the risk of heart disease or stroke by 15% -20%, which is consistent with clinical trial results. However, for a wider patient population, the number of beneficiaries is expected to increase to 44 million. Based on this estimate, if all eligible patients receive GLP-1 treatment, 34000 cases of heart disease and stroke can be avoided annually. Experts say that GLP-1 drugs have had a profound impact on the field of cardiovascular care, and using them as a primary prevention measure is expected to further drive this change.
In fact, semaglutide is not just a weight loss medication, but also a health enhancer. Yale University cardiologist Dr. Harlan Krumholts strongly agrees with this, believing that the true value of these drugs lies in improving health conditions. However, for those who hesitate whether to use these drugs to treat obesity, the additional evidence that these drugs are beneficial to the heart will undoubtedly have a huge impact.
Dr. Krumholts suggests that we should re-examine this issue and strive to classify patients into low-risk categories to help them continuously improve their quality of life. Dr. Brendan Everett, a cardiologist at Brigham and Women’s Hospital in Chicago and an associate professor at Harvard Medical School, has also prescribed GLP-1 drugs for some patients. The new report also reveals an important piece of information: artificial intelligence models accurately predict a decrease in cardiovascular risk in patients less than two years after they start using GLP-1; In contrast, Novo Nordisk’s experiment took more than three years. There is still a huge opportunity for the United States to improve cardiovascular health.
Heart disease is the leading cause of death in the United States, followed closely by stroke, ranking fifth. With the increasing popularity of GLP-1 drugs, experts are calling for more data to help healthcare providers allocate existing resources rationally, ensuring that these drugs can truly work and benefit the patients who need them the most.
